Moderna Net Income From Continuing Ops from 2010 to 2026
| MRNA Stock | USD 42.23 2.12 5.29% |
Net Loss | First Reported 2016-12-31 | Previous Quarter -825 M | Current Value -200 M | Quarterly Volatility 1.6 B |
Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna's main balance sheet or income statement drivers, such as Interest Expense of 29 M, Selling General Administrative of 1.2 B or Total Revenue of 1.8 B, as well as many indicators such as Price To Sales Ratio of 5.61, Dividend Yield of 4.0E-4 or PTB Ratio of 1.6. Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules.
Moderna | Net Income From Continuing Ops | Build AI portfolio with Moderna Stock |
Analyzing Moderna's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Moderna's current valuation and future prospects.
Latest Moderna's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Moderna over the last few years. It is Moderna's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moderna's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Moderna Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 200,001,055 | |
| Coefficient Of Variation | 2,076 | |
| Mean Deviation | 2,372,235,046 | |
| Median | (216,211,000) | |
| Standard Deviation | 4,151,911,599 | |
| Sample Variance | 17238369.9T | |
| Range | 16.3B | |
| R-Value | (0.09) | |
| Mean Square Error | 18244881.9T | |
| R-Squared | 0.01 | |
| Significance | 0.74 | |
| Slope | (72,434,719) | |
| Total Sum of Squares | 275813918.8T |
Moderna Net Income From Continuing Ops History
About Moderna Financial Statements
Moderna stakeholders use historical fundamental indicators, such as Moderna's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Moderna investors may analyze each financial statement separately, they are all interrelated. For example, changes in Moderna's assets and liabilities are reflected in the revenues and expenses on Moderna's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Moderna. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -4.1 B | -3.9 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out the analysis of Moderna Correlation against competitors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. Expected growth trajectory for Moderna significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Moderna assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.85) | Earnings Share (7.26) | Revenue Per Share | Quarterly Revenue Growth (0.30) | Return On Assets |
Understanding Moderna requires distinguishing between market price and book value, where the latter reflects Moderna's accounting equity. The concept of intrinsic value - what Moderna's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Moderna's price substantially above or below its fundamental value.
Understanding that Moderna's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Moderna represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Moderna's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.